glp-1 drugs and breast cancer cancer: use may substantially lower risk New study links GLP-1 drugs
Description
Besides animal trials, there are clinical data that support the neuroprotective properties of GLP-1 RAs
I am a passionate, curious, funny, and empathetic person
Company Insights Novo Nordisk A/S Eli Lilly and Company AstraZeneca Sanofi Amgen, Inc
This vastly exceeded the 14.9% average weight loss with semaglutide 2.4 mg weekly in the STEP-1 trial
Cases have required hospitalization
Another GLP-1 analog, liraglutide (Saxenda), was FDA-approved for weight loss in 2014
